Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevelamer carbonate TID in hyperphosphatemic chronic kidney disease patients not on dialysis
2007-003885-16Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Jul 2008
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hyperphosphatemia and chronic kidney disease (CKD) comparing Sevelamer carbonate TID with Placebo TID (2 arms). Primary endpoint: Serum phosphorus change from baseline to Week 12/Titration Period Early Termination. Started Jul 2008; status: terminated.
02
Drugs
sevelamer carbonate
03
Conditions
hyperphosphatemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on 2007-003885-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003885-16.